Ozempic vs. Tirzepatide vs. Retatrutide
What's the difference, and what does the science actually say?
You've probably heard of Ozempic. Maybe Mounjaro. And now there's growing interest in retatrutide. Here's a straightforward look at how these compounds differ, what studies have found, and what researchers still don't know.
One pathway. Two pathways. Three pathways.
These compounds interact with hormone receptors involved in appetite, blood sugar and energy regulation. More receptor targets don't automatically mean a medication is better, or safer.
Semaglutide
Targets GLP-1. Well-studied, with approved products for specific medical indications.
Tirzepatide
Targets GLP-1 + GIP. Approved products, with substantial clinical evidence in metabolic health.
Retatrutide
Targets GLP-1 + GIP + glucagon. Being studied in clinical trials; not an approved treatment.
How do they compare?
A quick comparison of the important differences.
| Feature | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Names you may hear | Ozempic, Wegovy | Mounjaro, Zepbound | Reta (informal abbreviation) |
| Receptor activity | GLP-1 | GLP-1 and GIP | GLP-1, GIP and glucagon |
| Clinical focus | Diabetes, obesity and related indications | Diabetes, obesity and related indications | Investigational studies of obesity and metabolic conditions |
| Approval status | Approved products; indications vary | Approved products; indications vary | Investigational; not approved for public use |
| Evidence maturity | Extensive randomized and real-world evidence | Extensive randomized and growing real-world evidence | Phase 2 and reported Phase 3 findings; ongoing trials and regulatory review remain distinct from approval |
| Important distinction | Ozempic and Wegovy contain the same active ingredient but are not interchangeable brands for every indication | Mounjaro and Zepbound contain the same active ingredient but have distinct labels | Research results are not equivalent to regulatory approval |
Brand availability, indications and labeling differ by country. Consult current Health Canada product monographs for Canadian specifics.
What have weight-loss studies found?
Results can look dramatic in headlines. The context, who was studied, at what dose, and for how long, matters just as much.
Published head-to-head study: tirzepatide vs. semaglutide
In the 72-week SURMOUNT-5 trial involving adults with obesity but without diabetes, average body-weight reductions were 20.2% with tirzepatide and 13.7% with semaglutide. These results are from the studied treatment regimens, not every brand or dose. [1]
Bar scale: 0–25% mean body-weight reduction. Source: SURMOUNT-5, 72 weeks. This is a direct comparison within one trial.
What about retatrutide?
A published Phase 2 trial reported up to 24.2% mean weight reduction at 48 weeks in one retatrutide study group. That is promising, but the trial used a different population and protocol from SURMOUNT-5. [2]
Also, an average trial result is not a prediction of what any one person will experience.
Why do these pathways matter?
The body uses multiple chemical signals to coordinate appetite, digestion, insulin release and energy balance.
Involved in fullness, appetite regulation, glucose-dependent insulin secretion and slowing stomach emptying.
An incretin hormone involved in glucose-dependent insulin secretion and metabolic signaling.
Influences liver glucose production and energy metabolism. Its effects are more complex than simply “burning fat.”
The rationale behind retatrutide is that engaging all three receptors may produce a different metabolic response. Whether that translates to a superior benefit-risk balance requires robust clinical evidence.
What about side effects?
These compounds are not risk-free. Known risks and the amount of long-term safety data differ.
Common digestive effects
Nausea, vomiting, diarrhea, constipation and abdominal discomfort can occur. Digestive side effects are often reported during treatment initiation or dose escalation.
Other important medical risks
Depending on the specific medicine, labeling and trials discuss issues such as gallbladder disease, pancreatitis, dehydration, kidney complications related to fluid loss, severe gastrointestinal effects, and low blood sugar when combined with certain diabetes drugs. Approved products also have specific contraindications and warnings, including thyroid C-cell tumor warnings in certain jurisdictions.
What's still unknown about retatrutide?
Longer-term safety and comparative outcomes are still being studied. Trials have reported gastrointestinal adverse events and heart-rate increases. Retatrutide is investigational and should not be presented as an approved option.
Does “research peptide” mean it's safe to buy?
No. “Research use only” does not establish purity, sterility, safety or authorization for human use. Health Canada warns about unauthorized injectable peptides sold online. [4]
Still have questions?
Is Ozempic the same as semaglutide?
Ozempic is a brand of semaglutide. Wegovy also contains semaglutide, but their labeled indications and dosing differ.
Is Mounjaro the same as tirzepatide?
Yes. Mounjaro contains tirzepatide, as does Zepbound. Approved uses and brand availability depend on jurisdiction.
Is tirzepatide more effective than semaglutide?
In the published SURMOUNT-5 trial, tirzepatide produced greater average weight loss than semaglutide over 72 weeks in the studied population and regimens. Individual outcomes vary. [1]
Is retatrutide better than tirzepatide?
Retatrutide has shown substantial weight reduction in clinical trials, but separate trial results cannot establish superiority. Direct comparative evidence and fuller safety data are needed.
Is retatrutide approved in Canada?
Retatrutide is investigational, not an approved medication for public use. Status checked October 11, 2026 against Lilly’s current information. Consult current regulatory information when making healthcare decisions.
Are all peptides weight-loss drugs?
No. Peptides are a broad category of molecules. Only certain peptide-based medicines have established roles in weight management, and many compounds discussed online have limited human evidence.
Curious about peptides? Start with the evidence.
Explore the basics or learn how researchers investigate different compounds. No hype, no shortcuts.
Research and further reading
- Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. New England Journal of Medicine (2025). Read on PubMed ↗
- Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity, A Phase 2 Trial. New England Journal of Medicine (2023). Read the study ↗
- Health Canada. Drug Product Database. Check Canadian approvals ↗
- Health Canada. Recalls and safety alerts. Review safety alerts ↗
Editorial note: This page distinguishes published head-to-head data from separate early-stage studies. Research context reviewed October 11, 2026. Retatrutide remains investigational; newer Phase 3 findings are linked separately above. Canadian brand indications should be checked against current product monographs.
RELATED PEPTIDE GUIDES
General education only. This article is not medical advice or a recommendation to obtain or use investigational products.